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Abstract. Despite over the last decades, cardiovascular research has significantly enhanced our understanding of the
atherosclerotic process, the molecular mechanisms underlying the pathology remain mostly unclear. In fact, the current 
diagnostic modalities do not inform clearly on the cellular and molecular processes that drive the development of 
atherosclerotic pathology and each of the imaging techniques has advantages and limitations in terms of radiation 
exposure, reproducibility, sensitivity, resolution and costs. Therefore, to overcome the limitations of individual imaging 
modalities and develop novel and preventive strategies, we need additional approaches to detect the atherosclerotic 
plaques’ formation in patients at high risk for clinical events. In this context, a new dimension of information lie in the
molecular imaging that allows to get a better knowledge of biological phenomena. In addition, multimodal imaging 
approaches play a pivotal role for the earlier detection of pathological process. Here, we provide a critical analysis of the
various imaging modalities currently used in clinical and nanotechnology approaches based on the development of bio-
nanocarriers for detection of cardiovascular diseases.
ATHEROSCLEROSIS AND DIAGNOSIS
Cardiovascular disease continues to be the leading cause of death in the Western world [1] and it is caused 
mainly by atherosclerosis. It is a multifactorial systemic disease characterized by arterial wall thickening and rigidity 
and the formation of the characteristic plaques that developed simultaneously in medium and large-sized arteries, 
inducing a blood flow reduction with different complications [2]. This inflammatory pathology that has origins in 
childhood and occurs decades before the disease becomes clinically apparent (cardiac arrest, acute myocardial 
infarction or stroke) [3,4]. The pathogenesis of atherosclerosis has been the subject of many scientific works and the 
major players involved in this process are endothelial cells, inflammatory and immune cells (mainly macrophages 
and T cells), and intimal smooth muscle cells (SMCs) [5,6]. For many years it was believed that the disease was 
only characterized by a passive accumulation of cholesterol in the vessel wall, but, nowadays, it is known that the 
evolution of the lesion is much more complex and not fully clarified. In addition, the degree of luminal stenosis is 
only indirect indicator of atherosclerotic process [7].
At the beginning, our understanding of the atherosclerotic pathology is mainly based on postmortem 
examinations of human coronary arteries or analysis of resected surgical specimens from patients who underwent 
carotid endarterectomy. In recent years, several imaging techniques, invasive and noninvasive, are available to 
detect and display different characteristics of atherosclerotic lesions of clinical interest [8]. The choice and 
applicability of each imaging technique depend not only on its diagnostic efficacy but also on the type of questions 
being asked. Unfortunately, these imaging modalities, neither characterize nor correlate the image parameters with 
histopathological lesion types, which are more clinically relevant. Most of the standard imaging modalities 
characterize some of the morphological and functional features of the vascular lesion, but a quantitative evaluation 
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of atherosclerotic disease during its natural history and following therapeutic interventions are necessary for 
understanding the stabilization or progression of the disease and for selecting suitable medical or surgical 
interventions.
This work highlights the latest knowledge about the role of imaging and future research directions based on 
nanotechnology approaches in atherosclerosis diagnosis.
IMAGING TECHNIQUES FOR ATHEROSCLEROSIS
Angiography
Initially, contrast angiography has been the gold standard imaging technique for atherosclerosis, providing 
information about site and severity of luminal stenosis, but it is unable to detect atherosclerotic lesions that do not 
protrude into the lumen and does not give information about plaque composition or vulnerability [9].
Unfortunately, the positive remodeling does not allow to assess the integrity of the arterial lumen in case of 
cardiovascular disorders subclinical. Another limitation of angiography is that underestimate the degree of local 
stenosis. Furthermore, it is an invasive technique which can cause complications, is highly observer dependent and 
not very reproducible [9,10]. For all these reasons, other imaging modalities have been examined for the 
atherosclerotic process.
Intravascular Ultrasound (IVUS)
Currently, the use of Intravascular Ultrasound (IVUS) is confined to research or for interventions (ie.
angioplasty), because it is invasive technique [4]. This imaging modality allows an in vivo characterization with a 
resolution [11] of around 10 μm and direct assessment of coronary plaque volume and plaque morphology 
delineating the thickness and vessel wall structures [12].
Thus, IVUS allows tomographic assessment of lumen area and the composition of atherosclerotic plaque, whereas 
Angiography depicts a two-dimensional (2D) of the lumen vessel. In summary, IVUS is able to visualize 
atheromatous plaques which are angiographically invisible [13]. An important application of IVUS is the potential
identification of high-risk plaques of rupture.
Magnetic Resonance Imaging (MRI)
Magnetic Resonance Imaging (MRI) is a highly flexible, reproducible and noninvasive imaging modality. In 
contrast to the other medical imaging methods which expose patients to ionizing radiation, MRI uses strong non-
ionizing electromagnetic fields in the radio frequency range, offers excellent spatial resolution, is not operator 
dependent, and provides 3D data [14]. Compared to other imaging techniques (i.e. nuclear medicine techniques), it 
shows low sensitivity and long acquisition time [15]. The use of contrast agents (CAs) are often required in MRI 
scans in order to improve the enhancement of MRI signals [16].
This technique allows evaluating the arterial vascular tree and its use in the diagnosis of carotid atherosclerotic 
process has been validated and allows to obtain detailed information about the macrostructure of the plaque [14]. In 
addition, MRI is capable of discriminating between different component of plaque, such as lipid core, fibrous cap, 
intraplaque hemorrhage and calcification, and has the potential to identify vulnerable plaque before an ischemia [3].
Generally, these elements appear as isointense (ie. Lipid component on T1-weighted sequences), others hypointense 
(ie. calcium within the plaque on T1- and T2-weighted sequences) or hyperintense (ie. the fibrous cap) [17].
The carotid arteries are vessels of good caliber that are not subjected to movement. Thus, they are ideal for 
noninvasive imaging studies. In contrast, the motion artifacts, the reduced size, the position and the tortuosity of the 
coronary arteries make their visualization technically difficult [14]. Evaluation of the arterial wall , although of great
clinical utility, turns out to be technically more difficult. Furthermore, the thickness of the coronary artery wall 
correlated with the temporal progression of the medical signals remains to be investigated.
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Computed Tomography (CT)
Computed Tomography (CT) is a noninvasive imaging modality and is useful for evaluation of the arterial 
calcification, an early indicator of atherosclerosis. It provides a high temporal and spatial resolution and allows 
detailed anatomical visualization of atherosclerotic coronary disease and other cardiac abnormalities in medium and 
large-sized vessels [8]. Currently, the technical limits of CT are: poor soft tissue contrast and poor identification of 
subcomponents plaque. In addition, unlike MRI, CT exposes patients to high radiation dose and the ionated CAs
[18].
CT scans can be performed with or without administration of contrast agents. In the first case, the diagnostic 
technique allows detecting non-calcified plaque components, while, in the second case, the coronary calcium [19].
Positron Emission Tomography (PET)
Unlike CT or MRI, which show anatomic detail, Positron Emission Tomography (PET) is a noninvasive nuclear 
imaging technique and provides quantitative in vivo assessment of physiological and biological phenomena. This 
modality necessitates the injection of a small quantity of radioisotopes used as tracers [20]. PET agents provide a 
better functional assessment of atherosclerotic plaques than tracers used in current nuclear imaging modalities.One 
of the most used PET agents, for understanding the pathological stages of vascular lesion in vivo, is 2-deoxy-2-18F-
fluoro-D-glucose (18F-FDG), a synthetic molecule that competes with glucose for uptake into metabolically active 
cells (ie. inflammatory cells), but is not metabolized [21]. The advantage of PET over other imaging modalities, 
such as SPECT (Single Photon Emission Computed Tomography), is represented by high spatial resolution and 
contrast resolution and superior sensitivity that allow detection of picomolar tracer concentrations in the arteries
[22]. Unfortunately, limited spatial resolution (~ 2 mm) means that images must be coregistered with CT or MRI for 
precise anatomical localization of 18F-FDG uptake. Several clinical and preclinical studies of atherosclerosis show 
that a high macrophage density correlates with enhanced 18F-FDG uptake in vessels with plaque. Other works, 
instead, have demonstrated that the increased uptake of 18F-FDG, a transient phenomenon, in the large arteries of 
patients correlated with atherogenic risk factors. Furthermore, this technique is not yet standardized and 18F-FDG 
uptake or changes in 18F-FDG uptake, correlated to cardiovascular events, can generate false positives or negatives
[23].
NONINVASIVE MRI MOLECULAR IMAGING
As described previously, MRI represents the unique technique that combines excellent soft tissue discrimination 
with high spatial resolution without the use of ionizing radiation. Nevertheless, this imaging modality is limited by 
its low sensitivity and requires the use of CAs to display the atherosclerotic plaques clearly. This restriction may be 
overcome with a noninvasive molecular imaging approach, considered an in vivo equivalent to 
immunohistochemical techniques and based on a signal imaging element encapsulated or conjugated to a carrier that 
transports a ligand that is then recognized by the target molecule. In fact, this strategy can facilitate early diagnosis, 
has the potential to image the pathophysiological process of the disease before the onset of symptoms and can be 
applied to follow the efficacy of therapy. In this scenario, the advantage of MRI resides in its ability to provide not 
only anatomical but also functional information quantifying specific biological processes within a single imaging 
modality. A variety of molecular targets has so far been successfully employed in preclinical models of 
cardiovascular disease to identify typical features associated with plaques that are prone to rupture. Examples of 
biomarkers are shown below: cell adhesion molecules (VCAM 1 or E-selectin) [24], extracellular matrix, 
lipoproteins, smooth muscle cells, macrophages, phosphatidy???????? ???? ????? ???????? [25,26]. At first, the CAs
were conjugated with monoclonal antibodies or specific peptides, but excellent results are then obtained with 
nanoparticles (NPs) that combine a high binding affinity for the target zone with the capacity to transport a sufficient 
amount of a contrast agent. The most widely employed NPs are: superparamagnetic iron oxide (SPIO), micelles, 
liposomes dendrimers and polymeric nanoparticles [26-28]. Table 1 summarizes the main diagnosis applications of 
these nanovectors. In this section, we will focus on recent progress in the use of nanoparticles for molecular MR 
imaging in atherosclerosis disease.
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TABLE 1. Nanovectors for diagnostic applications
Nanocarrier Pros Cons Example Target Application Ref
Micelle
Biocompatibility
Biodegradability
Easy chemical 
modification
High instability
Cannot be stored
Must be made 
fresh
(MDA2, E06, 
and IK17)-
labelled Gd-
micelles
OSE (Active 
targeting)
Oxidative 
Stress
[54]
Dendrimer
Size and shape 
controllability
Water solubility
Biocompatibility
Non-specific
Cytotoxicity
Rapid clearance
MDA2-
labeled 
MnDTPA-G8 
PAMAM 
dendrimers
OSE (Active 
targeting)
Oxidative 
Stress
[70]
SPION
Robustness and 
stability
Resistance to 
enzymatic 
degradation
Long circulation 
time
Non-
biodegradability
Limited 
biocompatibility
(VHPKQHR)-
labelled 
MIONs
USPIOs
SPIONs 
coated with 
dextran
VCAM-1 or 
E-selectin
(Active 
targeting)
Macrophages
(Passive 
targeting)
PS (Active 
targeting)
Endothelial 
activation
Inflammation
Apoptosis
[24, 
40]
[34-37]
[39]
Liposome
Easy 
conjugation and 
functionalization
Rapid cellular 
uptake
Biocompatibility
Rapid clearance
High production 
costs
Low solubility
Gd-containing 
PS liposomes
VCAM-1 or 
E-selectin 
(Active 
targeting)
Macrophages 
(Passive 
targeting)
PS (Active 
targeting)
Endothelial 
activation
Inflammation
Apoptosis
[62]
Polymer
Water solubility
Non-toxicity
Biodegradability
Time-consuming 
preparation 
processes
Expensive 
equipment
Gd-loaded 
PLGA/RGD
RGD 
Sequence 
(Active 
targeting)
Thrombosis [51]
ABBREVIATIONS: Gd, Gadolinium; USPIOs, ultrasmall superparamagnetic iron oxide nanoparticles; SPIONs,
superparamagnetic iron oxide nanoparticles; VCAM-1, vascular cell adhesion protein 1; DTPA, diethylenetraminepentaacetic 
acid; PS, Phosphatidylserine; OSE, Oxidation-specific epitopes; Mn, manganese; MIONs, monocrystalline iron oxide 
nanoparticles; PAMAM, poly(amidoamine); RGD, arginylglycylaspartic acid; MDA2, E06 and IK17, oxidation-specific 
antibodies; VHPKQHR, linear peptide for VCAM-1; PLGA, poly(lactic-co-glycolic) acid.
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Superparamagnetic Iron Oxide Nanoparticles (SPIONS)
Several MRI strategies to display the atherosclerotic lesions were successfully developed using NPs platform
[29,30]. In effect, their chemical, physical and pharmacokinetic characteristics and the ability to transport high 
payloads make them highly suited to cellular and molecular imaging of atherosclerotic lesions.
Generally, two categories of contrast agents are used for molecular MR imaging of atherosclerotic plaques: 
superparamagnetic iron oxide nanoparticles (SPIONs) and nanoparticles that incorporate gadolinium (Gd) chelates
[27,31]. SPIONs represent the main platform used and are composed of an iron oxide core formed by magnetite 
(Fe3O4) and/or ??????????????2O3) and coated with a polysaccharide, synthetic polymer, or monomer, which make 
them water soluble, prevent their aggregation and improve biocompatibility [32]. Moreover, the combination “core-
shell” influences the pharmacodynamic and pharmacokinetic features of the final product. Passive targeting of these 
nanocarriers dependent on the control of parameters such as the surface charge and hydrodynamic radius that affect 
circulation time of the nanoparticles, accessibility to tissues, opsonization, and so on. Differently, active targeting 
takes advantage of nanoparticle’ surface modifications with monoclonal antibodies or peptides [32]. Generally, the 
term SPIO can be used to refer to: standard SPIO (SSPIO, 60-150 nm), ultrasmall SPIO (USPIO, <50 nm),
monocrystalline iron oxide nanoparticles (MION,~30 nm) and cross-linked iron oxide (CLIO) [33]. Phagocytic cells 
of reticuloendothelial system (RES) take up injected SPIONs spontaneously by endocytosis or phagocytosis 
allowing a rapid accumulation of these particles at the level of the lesion of interest [34]. This system have been 
characterized as MRI contrast agents for the imaging of the plaque inflammation, which represents one the most of 
the features of high-risk atherosclerotic plaques [29]. In particular, Ruehm and coworkers [34] demonstrated that in 
hyperlipidemic rabbits there is an accumulation of USPIOs in plaques with high macrophage content and that this 
phenomenon induced MR signal changes. For this reason, Kooi and colleagues [35] investigated the detection of 
macrophages in human atherosclerotic plaque. The results showed that the use of a USPIO agent, Sinerem® 
(Guerbet; Ferumoxtran-10), accumulated mainly in macrophages in human atherosclerotic lesions prone to rupture, 
it induced significant decrease of signal T2* images obtained 24 hours after intravenous administration but not in the 
images obtained after 72 hours (washout phenomenon). This information suggested that USPIO-enhanced MRI is as 
a promising method for the in vivo differentiation between low- and high-risk plaques and additional studies 
conducted by Trivedi et al. [36] confirmed these preliminary results, suggesting furthermore that there is a process 
of accumulation and excretion of USPIOs.
A representative example of a study, in which MRI is used to monitor the target site accumulation of USPIOs, is 
published by Tang and colleagues [37]. In summary, the researchers explored whether there is a difference in the 
degree of inflammation between asymptomatic and symptomatic patients.The results suggested that one inflamed 
symptomatic vascular bed can be increase the risk of other arterial vessels to become inflamed. Finally, preclinical 
(atheromatous rabbits and ApoE knockout mice) and clinical studies of Sinerem® for noninvasive MRI assessment 
of atherosclerotic plaque inflammation are summarized by Tang et al. [38].
An example of active targeting, for development of a non-invasive method to detect vulnerable plaque prior 
rupture in vivo, is reported by Smith et al. [39]. In this investigation SPIONs consisting of an iron oxide core coated 
with dextran and conjugated to a cellular protein, Annexin V, that recognizes apoptotic cells by specific molecular 
interaction with Phosphatidyl Serine (PS). They tested in two rabbit models of atherosclerosis and MRI was 
performed with a 4.7 T small animal MRI system. The results were confirmed by further histological investigation
and vascular targeting by the system, SPIONs-Annexin V, was atheroma-specific. In addition, the administered dose 
was significantly lower than the particles without target in the same animal model. Therefore, the presence of a 
biomarker, as Annexin V, can provide additional support for the diagnosis of vulnerable plaque.
Nahrendorf et al. [24], instead, functionalized MION with linear peptide (VHPKQHR) for targeting of the vascular 
cell adhesion molecule-1 (VCAM-1), which is a biomarker expressed at early stages and progression of 
atherosclerotic lesions. Even in this case, the conducted studies in animal models showed that the anatomical area of 
interest became dark (hypointense signal) after the injection of the nanoparticles. Kang and colleagues [40] prepared 
similar system using CLIO nanoparticles with E-selectin antibody fragments to detect E-selectin in endothelial cells. 
The expression of this molecule is induced by an inflammatory cytokine (interleukin-???????????????????d, a high
decrease in T2* signal is present in the treated mice with interleukin-????????????????????????????????
Many research groups have long studied the use of these carriers based on the models mentioned above in 
atherosclerosis detection and several scientific works are reported in the literature [41], but none is currently 
approved for clinical diagnostic evaluation and there are not others in clinical development.
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Polymeric Nanoparticles (PNS)
Recent progress in synthetic polymer chemistry have produced a plethora of polymeric nanoparticles (PNs) in 
nanomedicine field for diagnostic applications [42, 43]. PNs can be made from organic polymers or inorganic 
materials and according to their intended application, nanoparticles can be engineered to impart the required 
properties [44]. Biopolymer nanoparticles can give several advantages: biodegradability, biocompatibility, effective 
encapsulation of active molecules, long circulation half-life, controllable size (sub-micron) that permits 
biodistribution different to the small molecules and easy surface functionalization for delivery to the site of interest
[45]. Therefore, the versatility of these structures makes them an attractive platform for developing molecular 
imaging agents. The strategy to prepare PNs with imaging functionality is to incorporate materials or functional 
groups with some characteristic that makes them a new promising tool for the diagnostic. Generally, the CA can be 
covalently conjugated or physically encapsulated within polymeric matrix [46-49]. In the first case, the molecules 
with imaging properties are connected to polymeric backbone and there may be nonhomogeneous distribution and 
poor loading efficiency of CA on the polymer surface. Conversely, in the latter case, the system offers high loading 
efficiency and homogenous distribution of contrast media within the polymeric matrix. Initial characterization of 
polymeric nanoparticles containing gadolinium chelate (Gd-DTPA) as CA for enhanced MRI is reported by Doiron 
et al. [50]. In this work a water-in-oil-in-oil double emulsion solvent evaporation technique was used to encapsulate 
the CA in a poly(lactide-co-glycolide) (PLGA) or polylactide-poly(ethylene glycol) (PLA-PEG) particle for the 
transport of MRI agent for the detection of staged atherosclerosis. PLGA particles showed negative zeta potentials, 
while PLA-PEG particles had neutral zeta potentials. In vitro experiment showed that cytotoxicity of these particles 
on human umbilical vein endothelial cells (HUVEC) was minimal, while MRI in vitro experiment demonstrated that 
the relaxivity of the PLGA particles is similar to that of unencapsulated Gd-DTPA. Recently, Zhang and colleagues
[51] have successfully synthesized using water in oil in water method and characterized a new type of delivery 
system based on PLGA. In this case, (Gd)-loaded PLGA nanoparticles show on the surface a specific peptide 
sequence (Arg-GlyAsp-Ser, RGDS) for the detection of thrombus at the molecular level. The results of in vitro 
experiments suggest that these molecular probes can be used for detection of thrombus with a longitudinal relaxation 
similar to commercial CAs.
Recently, our group is focused on the use of biomaterials to improve the healthcare services in the field of MRI and 
potentially for atherosclerosis diagnosis. Russo et al. [47], for example, report a new Hyaluronic Acid (HA) 
nanoprobe (35 nm), obtained by a controlled and continuous microfluidic process, which entraps CAs for MRI. In a 
subsequent work, the impact that hydrophilic biopolymer networks have on the relaxivity of Gd-based CAs has been 
analysed and the concept of “Hydrodenticity” has been defined to describe the ability of these biopolymers to 
enhance the properties of the metal chelate, as reported by Ponsiglione et al [48]. Vecchione et al. [49], instead, 
describe a core-shell architecture for multimodal imaging applications obtained by a modified complex 
coacervation. The relaxivity of Gd-DTPA nanoconstructs is more than four times higher than the relaxivity 
measured for free Gd-DTPA in solution.
Micelles
Micelles are self-assembled nanostructures composed by amphiphilic molecules (lipid or polymer). They can be 
made mainly by a hydrophobic core and externally a hydrophilic surface, characteristics that allow encapsulating
therapeutic or diagnostic agents within the micelles. A first in vitro study is conducted by Lipinski et al. [52] that 
evaluated the uptake of micelles linked to ??????? antibody (immunomicelles) for macrophages and containing Gd-
DTPA micelles, and a murine model of Apolipoprotein E knockout (ApoE KO) is used for ex vivo imaging of 
lesions. The micelles (size <100 nm) are made by lipid monolayers and the results of the experiments demonstrated 
that the immunomicelles are taken up by the macrophages compared to untargeted micelle and both micelles and 
immunomicelles are superior CAs compared to the others used in clinical practice. This enhancement is related to 
the content of macrophages, which is associated with plaques vulnerable to rupture. A limitation for this study is 
represented by long acquisition time. A similar approach was published by Mulder and coworkers [53]. The 
obtained results in this work are consistent with previously findings that show uptake of immunomicelles in cultured 
macrophages and in ex vivo atherosclerotic aorta [52]. Subsequently, Briley-Saebo et al. [54] conducted a study 
using micelles containing Gd and antibody (murine or human) that bind oxidation-specific epitopes (OSE). The aim 
of this work was to obtain a non-invasive in vivo imaging of atherosclerotic plaques rich of OSE by the use of MRI.
Also in this case, the results show that the active targeting allows to obtain a significant signal enhancement using 
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micelles containing a specific antibody and a good identification of atherosclerotic lesions. In another work [55], the 
same authors changed the model previously adopted in order to evaluate the in vivo MRI efficacy of manganese 
(Mn(II)) as molecular imaging probe for OSE. Mn is a paramagnetic metal ion, endogenous, and bio-compatible and 
DTPA is used as the chelating agent. The intracellular accumulation in intraplaque macrophages of targeted bio-
compatible Mn-micelles and de-metallation resulting in free Mn resulted in significant efficacy of contrast-enhanced 
MR imaging, allowing the visualization of atherosclerotic lesion through a non-invasive method.
Liposomes
Liposomes represent a delivery vehicle for active molecules (ie. imaging agents) and phospholipids are the main 
their constituent [56,57]. These amphiphilic molecules, consisting of a hydrophobic tail and hydrophilic head 
groups, confer to liposomes the ability to organize into spherical bilayer orientations in aqueous media. Generally,
they contain an aqueous core and are used to encapsulate hydrophilic molecules [58]. Liposomes can be classified
according to their lamellarity (uni-, oligo-, and multi-lamellar conformation), size, surface charge and preparation 
method [58,59]. These vesicular structures have been established for their passively and actively targeted 
applications, but they tend to accumulate in the liver and spleen due to recognition by RES. To avoid this 
phenomenon, researchers on liposome technology have progressed from traditional vesicles (“first-generation”) to 
“second-generation”, in which long-circulating time and stealth property are obtained by addition of polyethylene 
glycol (PEG) to the liposomes surface (process called PEGylation) [60,61].Because of the versatile possibilities of 
surface-modifications and active molecules encapsulation, liposomes have been extensively studied for delivery of 
bioactive agents in atherosclerotic lesions. Two approaches have been used to prepare liposome-based CAs: (1) 
encapsulation of the contrast agent into the liposome and (2) chemical conjugation of the MRI probe to the liposome 
membrane. An example of liposomes used for delivery to atherosclerotic tissue has been reported by Maiseyeu et al.
[62], where Gd-decorated liposomes enriched with phosphatidylserine (PS) were used for imaging of accumulated 
macrophages at atherosclerotic site in ApoE -/- knockout mouse models?? ????? ????????? ???????? ?? ???????????
enhancement of atherosclerotic plaque in vivo for molecular characterization of high-risk plaques. Based on similar
rationale of macrophage activity in atherosclerotic lesions, Resen et al. [63] and Mulder and coworkers [64] have 
reported the development and contrast-enhanced targeted MR imaging of vascular disease associated inflammation 
using Gd-liposomes.
Dendrimers
Dendrimers are a highly significant class of nanosystems that exhibits many attractive characteristics and plays 
an important roles not only as drug delivery carriers, but also as imaging agents [65]. In more detail, they are nano-
sized structures characterized by a controllable multibranched three-dimensional arrangement, globular shape, high 
functionality, small size and low polydispersity [66]. These structures offer three points for modification with 
diagnostic agents: the core, the branching zone and the branch extremities [67]. Therefore, active molecules may be 
encapsulated into the interior area or chemically/physically linked onto the nanovector surface. [68]. Their 
pharmacokinetics and pharmacodynamics features are not very clear and thus remain to be explored for their 
bioapplication [66]. In addition, the composition and size of dendrimer-based MR imaging agents influences their 
behavior. The pioneers in this field are Kobayashi et al. [69] that conducted a study about optimization of the 
performance of dendrimer-based MRI agents in vivo in comparison to Gd-[DTPA] using the poly (amido amine)
(PAMAM) and diaminobutane core polyaminoamine (DAB) for the preparation of MRI contrast agents. They 
observed that dendrimer-based MRI contrast agents are quickly excreted by the kidneys and also able to visualize 
vascular structures better than Gd-DTPA due to less extravasation. Therefore, these structures are retained in the 
body for a prolonged time. Recently, Nguyen and colleagues [70] have synthesized, characterized, and evaluated the 
MR efficacy of manganese (Mn) dendrimers targeted to OSE in murine models. Considering that dendrimers can be 
easily modified to allow for the addition of contrast agents and antibodies for targeted delivery, PAMAM-based 
dendrimers were chosen for their ability to load large amounts of Mn and DTPA is chosen as chelating agent. The 
results demonstrated that the administration of the targeted dendrimers allow to obtain a significant enhancement of 
vascular lesions in comparison to untargeted dendrimers. The analysis was only qualitative because the observed 
MR imaging signal did not correlate with the histological presence of OSE.
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CONCLUSIONS
Despite the progress in primary and secondary prevention and the growth of the knowledge base of 
atherosclerosis pathology, the incidence of myocardial infarction and stroke continues to remain high. Nowadays, 
the nanotechnology and the design of nanoscale devices seem to be a promising avenue for improving 
cardiovascular outcomes. The examples reported in this work include the use of NPs for MRI as tool for non-
invasively evaluating atherosclerotic plaques, but their application in atherosclerotic field is very limited so far. A
future goal in this field is represented by the combination of disease-specific biomarkers linked to the suitable 
carriers with MRI imaging modality in order to improve diagnosis and therapy of the atherosclerotic lesion.
Therefore, it is essential to broaden our current understanding of distinct stages of pathological process for the 
development of novel diagnostic approaches based on these concepts. In the end, potentially harmful effects of these 
new methodologies must be borne in mind.
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